-
2025-520582-51-00
5
2025-10-17
Hormone receptor positive breast cancer
-
2024-511166-36-00
5
2025-06-13
Moderate to Severe Plaque Psoriasis
-
2024-517004-11-00
5
2024-10-22
Chronic pulmonary aspergillosis
-
2024-510741-33-00
4
2024-06-27
Macular degeneration
-
2023-505277-32-00
5
2023-01-26
Diffuse Large B-Cell Lymphoma (DLBCL)
-
2022-500391-62-00
9
2023-01-19
Subjects with relapsed/refractory peripheral T-cell lymphoma (R/R PTCL
-
2023-509891-40-00
5
2026-04-28
Pulmonary arterial hypertension
-
2024-520205-39-00
5
2026-04-21
Traumatic brain injury
-
2025-523224-45-00
10
2026-03-30
Untreated, Unresectable or Metastatic Colorectal Cancer
-
2023-507545-28-00
6
2026-03-06
Elderly patients ≥ 65 years successfully treated with percutaneous cor
-
2025-521805-41-00
5
2026-02-18
Patients with HER2-positive, locally advanced or metastatic breast can
-
2024-516966-12-00
4
2026-02-13
Alzheimer’s disease
-
2024-515948-23-00
5
2026-02-06
Advanced pulmonary or gastroenteropancreatic poorly differentiated neu
-
2025-522860-34-00
5
2025-12-16
Chronic lymphocytic leukemia (CLL)
-
2025-522395-92-00
5
2025-12-15
metastatic oeso-gastric adenocarcinoma
-
2024-517136-21-00
5
2025-12-05
Renal Cell Carcinoma
-
2025-521178-33-00
4
2025-12-03
Chronic Hepatitis B Virus Infection
-
2025-521281-97-00
5
2025-12-02
Non-Small Cell Lung Cancer (NSCLC)
-
2024-517316-29-00
4
2025-11-07
Unresectable stage III Non-Small Cell Lung Cancer
-
2024-517131-52-00
5
2025-11-03
Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lym
-
2024-517232-22-00
5
2025-09-26
KRAS G12C-mutant, Locally Advanced Unresectable or Metastatic Colorect
-
2024-516099-13-00
5
2025-09-25
Severe Irritable Bowel Syndrome (IBS)
-
2024-511989-36-00
5
2025-09-24
Ewing Sarcoma
-
2023-505109-17-00
5
2025-08-27
Sickle cell disease